Evosep webinar

ASMS 2023 highlights: Automating end-to-end workflows

Available on demand

Get an overview of all the highlights of Evosep at ASMS 2023, including new research, talks and much more from the conference!

Saturday, June 3, 2023 – 5.30 – 9 PM – True Anomaly Brewing CO – 2012 Dallas St, Houston

Evosep User Meeting: Food for thought 

We were thrilled to announce our Evosep One user meeting during this year’s ASMS with informal hours of science presentations, networking and knowledge-sharing.

High-throughput analysis of deep plasma proteomes by enrichment of extracellular vesicles

Talk by PhD. Ole Østergaard, Proteomics Specialist at Novo Nordisk Foundation Center for Protein Research

Human plasma is an attractive source for protein biomarker discovery as it is in contact with essentially all organ systems in the human body and relatively easy to collect. However, plasma is also a challenging bio-specimen due to the high dynamic range of plasma proteins with quantification of typically only few hundred proteins in standard mass spectrometry (MS)-based proteomics workflow. Extracellular vesicles (EVs) are membrane-enclosed bodies shed constitutively from cells as part of both physiological and pathological processes. Enrichment of EVs from plasma followed by data-independent acquisition (DIA) MS-analysis using fast gradients on the Evosep One LC enables reproducible quantification of 10-fold more proteins from plasma including proteins associated with relevant pathology making this a powerful strategy in clinical proteomics.

Very large-scale cerebrospinal fluid proteomics for biomarker discovery in multiple sclerosis

Talk by Jakob Bader, PhD student, Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry

Proteomics in body fluids is challenged by the high range of protein abundances and the large cohorts required for biomarker studies. Here, we present a scalable and high-throughput mass spectrometry (MS) proteomics CSF workflow and validate it in a cohort of 6000 CSF samples from patients with various neurological conditions; detecting an average of 1300 proteins per sample. The system is built around the Evosep One chromatography system and the Bruker timsTOF Pro 2, utilizing a 21-minute gradient (60 samples per day) and data-independent acquisition (DIA) scheme. We characterize the robustness of the overall system, including on chromatography level. The large dataset obtained via this scalable workflow synergizes with machine learning to define markers for Multiple Sclerosis.

Accelerating drug development using precision proteomics for patient selection

Talk by Valentina Siino, Senior Scientist at Acrivon Therapeutics Inc.

With cancer being the major cause of death worldwide (Yaffe, 2019; WHO, 2022), and the field of oncology having the highest percentage of failed trials (32%) for drugs in phase II and phase III (Harrison et al. 2016), there is an unmet need for finding specific and reliable biomarkers. 

The Acrivon Predictive Precision Proteomic (AP3) method is specifically designed to overcome the limitations of traditional genetics-based methods and aims to match our precision oncology drug candidates to the patients whose tumors are predicted sensitive to them, independent of underlying genetic alterations. We have used AP3 to generate a predictive protein-based patient selection test, called OncoSignature®, for our lead asset, a CHK1/2 inhibitor that we are advancing in our potentially registrational Phase 2 clinical trial in three solid tumor indications based on predicted sensitivity to ACR-368. The ACR-368 OncoSignature test has been extensively evaluated, including in 2 blinded, prospectively designed biopsy studies on pretreatment tumor biopsies collected from patients with platinum-resistant ovarian cancer previously treated with ACR-368, demonstrating significant enrichment of responders. We have just received Fast Track designation from the Food and Drug Administration for the investigation of ACR-368 as a monotherapy for patients with OncoSignature-positive platinum resistant ovarian and endometrial cancers. 

The AP3 approach leverages unbiased differential global phosphoproteomic drug profiling using mass spectrometry and quantitative multispectral in situ imaging of tumor models, patient samples and clinical trial biopsies, to identify and evaluate biomarkers. The AP3 platform is also used to generate robust data outputs that result from analyzing benchmark clinical-stage compounds for the rational design of our preclinical drug candidates in parallel with developing patient selection capabilities, indication finding, rational drug combinations and drug resistance mechanisms. 

A complete and automated end-to-end sample preparation strategy for high-throughput and standardized proteomics

Talk by Dorte Bekker-Jensen, Scientist at Evosep

Proteomics is going through a significant paradigm shift and is rapidly evolving towards higher throughput and robust easier-to-use technologies. The use of short LC gradients combined with data-independent acquisition (DIA) has been a key aspect in this development. The Evosep One is designed for high-throughput and high-volume applications, where standardized methods with increasing robustness enable routine analysis of hundreds of proteomes per instrument per day. This has shifted the bottleneck for realizing high-throughput proteomics towards sample preparation creating a need for rapid, robust, and reproducible end-to-end automated workflows. Here, we combine our fully automated loading strategy for Evotips with fully automated sample handling functionalities in a modular setup and using it with protein aggregation capture (PAC) assisted digestion in an end-to-end standardized workflow.

Nicolai Bache, Head of Applications at Evosep (host)

MEET THE TEAM

This year we had representatives from our Applications-, Management-, Sales- and Product team.
Learn a little bit about the team at ASMS 2023 here. 

News